Alan Parker

Professor of Translational Virotherpies

Cardiff University

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Immunology Immunology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Alan Parker is a faculty member at Cardiff University in the United Kingdom. His research focuses on translational virotherapies, particularly in the areas of immune cell activation and tumor cell death, as well as the application of adenoviral vectors in cancer treatment and immunotherapies. Recent publications explore topics such as vaccine-induced thrombotic thrombocytopenia, the selective delivery of chemotherapy to pancreatic cancer, and enhancing the efficacy of adenovirus-based therapies.

Articles (17)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (6)

Carly Bliss

Lecturer in Cancer Immunology

Cardiff University

UNITED KINGDOM

View details

Matthew Rondina

Associate professor of Internal Medicine, Investigator of Molecular Medicine

University of Utah

UNITED STATES

View details

Florian Siebzehnrubl

Senior Lecturer

Cardiff University

UNITED KINGDOM

View details

Nigel Temperton

Professor of Molecular Virology

University of Kent

UNITED KINGDOM

View details

Alfonso Jaramillo

Professor of Synthetic Biology

University of Warwick

UNITED KINGDOM

View details

Awen Gallimore

Professor

Cardiff University

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Alan Parker

Research Interests

Explore related searches

Contact this professor

About

Articles (17)

Investigating endothelial cell transduction and hexon: platelet factor 4 binding of ChAdOx1 in the context of vaccine-induced thrombotic thrombocytopenia

An αvβ6-specific virotherapy expressing bispecific immune cell activators induces immune cell activation to mediate tumor cell death

GP73: the key to unlocking immunotherapies efficacy in solid tumors?

The αvβ6 integrin specific virotherapy, Ad5NULL-A20.FCU1, selectively delivers potent “in-tumour” chemotherapy to pancreatic ductal adenocarcinoma

Identification of cross reactive T cell responses in adenovirus based COVID 19 vaccines

The Immune System—A Double-Edged Sword for Adenovirus-Based Therapies

Capture and inactivation of viral particles from bioaerosols by electrostatic precipitation

Oncolytic Viruses and Immune Checkpoint Inhibitors: The “Hot” New Power Couple

Engineering Adenoviral Vectors with Improved GBM Selectivity

Broad sialic acid usage amongst species D human adenovirus

Engineering Cancer Selective Virotherapies: Are the Pieces of the Puzzle Falling into Place?

Pseudotyping Bacteriophage P2 Tail Fibers to Extend the Host Range for Biomedical Applications

ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome.

The Feasibility of Pressurised Intraperitoneal Aerosolised Virotherapy (PIPAV) to Administer Oncolytic Adenoviruses

To clot or not to clot? Ad is the question—Insights on mechanisms related to vaccine‐induced thrombotic thrombocytopenia

The Revolving Door of Adenovirus Cell Entry: Not All Pathways Are Equal

Pouring petrol on the flames: Using oncolytic virotherapies to enhance tumour immunogenicity

Collaborators (6)

Carly Bliss

Matthew Rondina

Florian Siebzehnrubl

Nigel Temperton

Alfonso Jaramillo

Awen Gallimore

Make your next move.